Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Radiation Fibrosis Syndrome 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Adenocarcinoma 1Inflammation 1Fibrosis 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 64Cisplatin 44Cetuximab 26Carboplatin 25Paclitaxel 19Magnetic Resonance Spectroscopy 19Radiotherapy, Intensity-Modulated 17Nivolumab 17Radiotherapy 16Specimen Handling 15Docetaxel 14Platinum 131,2-diaminocyclohexaneplatinum II citrate 12Taxes 8Fluorouracil 8Biopsy 8atezolizumab 6Radiation 6(225)Ac-DOTA-c(RGDyK) 6dostarlimab 5cemiplimab 5Ipilimumab 5Immunoglobulin G 5Cyclophosphamide 5Surgical Procedures, Operative 4Standard of Care 4Immune Checkpoint Inhibitors 4Disulfides 4Bevacizumab 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Losartan × 90 days × Clear all
NCT06211335 2026-03-12

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

University of California, Davis

Phase 1 Recruiting
24 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡